In 2010, the results of an open-label, international, phase III randomized controlled clinical trial (Trastuzumab for Gastric Cancer, ToGA) showed that the anti-HER2/neu humanized monoclonal antibody trastuzumab (Herceptin; Genentech, San Francisco, California) was effective in prolonging survival compared with chemotherapy alone in patients with HER2/neu-positive adenocarcinoma of the stomach and the esophagogastric
junction, (85) although overall survival was improved by less than 3 months.
As such, almost all endoscopic studies that used this endoscopic criterion for the EGJ are potentially flawed (12) and the biopsy at the so-called esophagogastric
junction almost always shows CLE.
Normalization of intestinal metaplasia in the esophagus and esophagogastric
junction: incidence and clinical data.
In some cases, all glands in a biopsy from the esophagogastric
junction stain extensively with AB, without having a single goblet cell (Figure 4, C).
Bankstahl, "NCT02661971--perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric
adenocarcinoma--RAMSES --a phase II/III trial of the AIO," ClinicalTrials.gov 2017 [cited 2017 Apr 23]; https://clinicaltrials.gov/ct2/show/ NCT02661971.
The 12 locations were as follows: 1: lesion at the esophagogastric
junction (AEGJ); 2: fornix; 3: lesser curvature of the body; 4: greater curvature of the body; 5: anterior wall of the body; 6: posterior wall of the body; 7: lesion across the angle; 8: lesser curvature of the antrum; 9: greater curvature of the antrum; 10: anterior wall of the antrum; 11: posterior wall of the antrum; and 12: lesion across the pylorus ring (APR) (Figure 2).
Tian et al., "A comparative study of two anticoagulation plans on the prevention of PVST after laparoscopic splenectomy and esophagogastric
devascularization," Journal of Thrombosis and Thrombolysis, vol.
Leap Therapeutics Inc (NASDAQ: LPTX)-- Phase 1/2 data for DKN-01 + Keytruda in esophagogastric
* Merck announced results from KEYNOTE-181, a Phase 3 trial investigating KEYTRUDA as monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric
junction carcinoma, which demonstrated a 31 percent reduction in the risk of death compared to chemotherapy in previously treated patients with advanced esophageal or esophagogastric
junction carcinoma whose tumors expressed PD-L1 (combined positive score [CPS] >10).
Obesity: a challenge to esophagogastric
It has been reported in gastric mucosa, at the esophagogastric
junction (EGJ), at the distal esophagus, and in Barrett esophagus (1-4); however, the pathogenesis of this entity is still unclear.
Should PET-CT be performed in esophagogastric